碘替酸 | 60019-19-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 碘替酸
• 英文名称: Iotetric acid
• 英文别名: 3-[[2-[2-[2-[2-[2-(3-carboxy-2,4,6-triiodoanilino)-2-oxoethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-2,4,6-triiodobenzoic acid
• CAS: 60019-19-4
• 化学式: C₂₄H₂₂I₆N₂O₁₀
• 分子量: 1259.9
• InChiKey: XPEPMWYMISJEEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  42
• 可旋转键数：
  17
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  170
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• Fluorinated carbohydrate conjugates
  申请人：McBride J. William

  公开号：US20050136001A1

  公开（公告）日：2005-06-23

  Disclosed are novel conjugates that include fluorinated carbohydrate molecules and methods for synthesizing the conjugates. The fluorinated carbohydrate molecule may include a radioisotope. The method of synthesizing the conjugate is useful for labeling selected molecules, and the conjugates may be useful in diagnostic or therapeutic methods. Particularly, the conjugates may be useful in diagnostic or therapeutic kits.

  本文披露了包括氟化碳水化合物分子的新型共轭物以及合成这些共轭物的方法。氟化碳水化合物分子可能包括放射性同位素。合成共轭物的方法可用于标记选择的分子，这些共轭物可能在诊断或治疗方法中有用。特别是，这些共轭物可能在诊断或治疗试剂盒中有用。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• D-amino acid peptides
  申请人：McBride J. William

  公开号：US20050025709A1

  公开（公告）日：2005-02-03

  The present invention provides compounds of the formula X—R 1 -D-[Dpr, Orn or Lys](A)-R 2 (Z)-D-[Dpr, Orn or Lys](B)—R 3 (Y)—NR 4 R 5 ; or R 1 (X)-D-[Dpr, Orn or Lys](A)-R 2 (Z)-D-[Dpr, Orn or Lys](B)—R 3 (Y)—NR 4 R 5 , in which X is a hard acid cation chelator, a soft acid cation chelator or Ac—, R 1 , R 2 and R 3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R 4 and R 5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. The present invention also provides methods of using these compounds and kits containing the compounds.

  本发明提供了公式X-R1-D-[Dpr、Orn或Lys](A)-R2(Z)-D-[Dpr、Orn或Lys](B)-R3(Y)-NR4R5或R1(X)-D-[Dpr、Orn或Lys](A)-R2(Z)-D-[Dpr、Orn或Lys](B)-R3(Y)-NR4R5的化合物，其中X是硬酸阳离子螯合剂、软酸阳离子螯合剂或Ac-，R1、R2和R3是独立选择的共价键或一个或多个D-氨基酸，可以相同或不同，Y是硬酸阳离子螯合剂、软酸阳离子螯合剂或不存在，Z是硬酸阳离子螯合剂、软酸阳离子螯合剂或不存在，A和B是半抗原或硬酸阳离子螯合剂，可以相同或不同，R4和R5是独立选择的硬酸阳离子螯合剂、软酸阳离子螯合剂、酶、治疗剂、诊断剂和H。本发明还提供了使用这些化合物的方法和包含这些化合物的试剂盒。